Recent advances in IBD therapeutics highlight promising agents under investigation, including Janus kinase (JAK) inhibitors, cytokine inhibitors (IL‐12/IL‐23), TNF‐like cytokine 1A (TL1A) inhibitors, and fatty acid modulators [39]. Here, TNFSF15 is linked to inflammatory bowel disease.